Crinetics price target raised to $97 from $96 at Citizens

Citizens analyst Jonathan Wolleben raised the firm’s price target on Crinetics (CRNX) to $97 from $96 and keeps an Outperform rating on the shares. Palsonify has been approved across the EU as the only once-daily oral therapy for adult acromegaly, with an initial launch planned in Germany and Austria, the analyst tells investors in a research note. Its oral dosing and perceived efficacy, especially in patients not responding to injectable treatments, position it as both a convenient and clinically meaningful alternative, the firm says.